Use

Mutations in the FLT3 gene, specifically internal tandem duplications (ITDs) and tyrosine kinase domain (TKD) mutations at codons 835 and 836, are among the most frequent molecular alterations in acute myeloid leukemia (AML), occurring in approximately 25%–30% of patients. These mutations drive constitutive activation of FLT3 kinase, enhancing malignancy, and are associated with poor prognosis, higher relapse rates, and reduced overall survival. A high mutant allelic ratio (≥0.5) particularly denotes adverse outcomes. Detection of FLT3 mutations is clinically significant, as patients may be eligible for FDA‑approved targeted therapy such as midostaurin.